Angiotensin II modulation of insulin-like growth factor I expression in the cardiovascular system

Trends in Cardiovascular Medicine

Volumn 6, Issue 6, 1996, Pages 187-193

  Delafontaine, Patrick ^a   Brink, Marijke ^a   Du, Jie ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN;

ANOREXIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 0030220076     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(96)00058-8     Document Type: Review

References (65)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828.
2. Anwar A, Delafontaine P: 1994. Hypertension increases insulin-like growth factor binding protein-4 mRNA levels in rat aorta. Hypertension 24:679-685.
3. Anwar A, Ku L, Delafontaine P: 1994. Angiotensin II regulates expression of insulin-like growth factor binding proteins in vascular smooth muscle cells [abst]. J Am Coll Cardiol 23:294A.
4. 3H-thymidine incorporation by angiopeptin in the aorta of rabbits after balloon angioplasty. Transplant Proc 21:3695-3696.
5. Baker KM, Chernin MI, Wixson SK, Aceto JF: 1990. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259:H324-H332.
6. Berk BC, Vekshtein V, Gordon HM, Tsuda T: 1989. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 13:305-314.
7. Bernstein KE, Berk BC: 1993. The biology of angiotensin II receptors. Am J Kidney Dis 22:745-754.
8. Binoux M, Hossenlopp P: 1988. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 67:509-514.
9. Brink M, Delafontaine P: 1995. Angiotensin II stimulates insulin-like growth factor I gene expression in rat heart [abst]. Circulation 92(Suppl 1):I-62.
10. Brink M, Wellen J, Delafontaine P: 1996. Angiotensin II produces weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97:2509-2516.
11. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM: 1995. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 92:8031-8035.
12. Carr JG, Stevenson LW, Walden JA, Heber D: 1989. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 63:709-713.
13. Cohick WS, Gockerman A, Clemmons DR: 1993. Vascular smooth muscle cells synthesize two forms of insulin-like growth factor binding proteins which are regulated differently by the insulin-like growth factors. J Cell Physiol 157:52-60.
14. The CONSENSUS Trial Study Group: 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.
15. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: 1991. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-456.
16. Delafontaine P: 1995. Insulin-like growth factor I and its binding proteins in the cardiovascular system [review]. Cardiovasc Res 30:825-834.
17. Delafontaine P, Anwar A, Lou H, Ku L: 1996. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest 97:139-145.
18. Delafontaine P, Lou H: 1993. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem 268:16,866-16,870.
19. Delafontaine P, Meng XP, Ku L, Du J: 1995. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem 270:14,383-14,388.
20. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM: 1994. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci USA 91:1686-1690.
21. Donohue TJ, Dworkin LD, Lango MN, et al.: 1994. Induction of myocardial insulin-like growth factor-1 gene expression in left ventricular hypertrophy. Circulation 89:799-809.
22. Du J, Delafontaine P: 1995. Inhibition of vascular smooth muscle cell growth through anti-sense transcription of a rat insulin-like growth factor I receptor cDNA. Circ Res 76: 963-972.
23. Du J, Meng X-P, Delafontaine P: 1996a. Transcriptional regulation of the insulin-like growth factor-I receptor gene: evidence for protein kinase C-dependent and -independent pathways. Endocrinology 137:1378-1384.
24. Du J, Sperling LS, Marrero MB, Phillips L, Delafontaine P: 1996b. G-protein and tyrosine kinase receptor cross talk in rat aortic smooth muscle cells: thrombin and angiotensin II induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor I receptor. Biochem Biophys Res Commun 218:934-939.
25. Dubey RK, Roy A, Overbeck HW: 1992. Culture of renal arteriolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ Res 71:1143-1152.
26. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr: 1995. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 95: 619-627.
27. Fath KA, Alexander RW, Delafontaine P: 1991. Hypertension modulates insulin-like growth factor I receptor mRNA levels [abst]. Circulation 84:11-397.
28. Fath KA, Alexander RW, Delafontaine P: 1993. Abdominal coarctation increases insulin-like growth factor I mRNA levels in rat aorta. Circ Res 72:271-277.
29. Geisterfer AA, Peach MJ, Owens GK: 1988. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62:749-756.
30. Gibbons GH, Pratt RE, Dzau VJ: 1992. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 90:456-461.
31. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ: 1994, Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 89:1511-1517.
32. Griffin SA, Brown WC, MacPherson F, et al.: 1991. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17:626-635.
33. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico: 1994. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115-1122.
34. Hanson MC, Fath KA, Alexander RW, Delafontaine P: 1993. Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy. Am J Med Sci 306:69-74.
35. Howell M, Orskov H, Frystyk J, Flyvbjerg A, Gronbaek H, Foegh M: 1994. Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. A preliminary study. Eur J Endocrinol 130:422-425.
36. Isgaard J, Wåhlander H, Adams MA, Friberg P: 1994. Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 23:884-888.
37. Ishida M, Marrero MB, Schieffer B, Ishida T, Bernstein KE, Berk BC: 1995. Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res 77:1053-1059.
38. ISIS-4 Collaborative Group: 1995. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345: 669-685.
39. Ito H, Hiroe M, Hirata Y, et al.: 1993. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87:1715-1721.
40. Jones JI, Clemmons DR: 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34.
41. Kajstura J, Cheng W, Reiss K, Anversa P: 1994. The IGF-1-IGF-1 receptor system modulates myocyte proliferation but not myocyte cellular hypertrophy in vitro. Exp Cell Res 215: 273-283.
42. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI: 1991. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 49:223-228.
43. Ketelslegers J-M, Maker D, Maes M, Underwood LE, Thissen J-P: 1995. Nutritional regulation of insulin-like growth factor-I. Metabolism 44(Suppl 4):50-57.
44. Khorsandi MJ, Fagin JA, Giannella-Neto D, Forrester JS, Cercek B: 1992. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation. Evidence for local bioactivity. J Clin Invest 90:1926-1931.
45. Lee MA, Bohm M, Paul M, Ganten D: 1993. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation 87.IV-7-IV-13.
46. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: 1995. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163.
47. Liu JL, Bishop SP, Overbeck HW: 1988. Morphometric evidence for non-pressure-related arterial wall thickening in hypertension. Circ Res 62:1001-1010.
48. Mann DL, Young JB: 1994. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105:897-904.
49. Marrero MB, Schieffer B, Paxton WG, et al.: 1995. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375:247-250.
50. Mooser V, Casley D, Trinder D, Paxton DL, Johnston CI: 1991. Reduction in left ventricular mass in normotensive and spontaneously hypertensive rats given enalapril. Clin Exp Pharmacol Physiol 18:341-344.
51. Pedersen EB, Danielsen H, Jensen T, Madsen M, Sorensen SS, Thomsen OO: 1986. Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. Eur J Clin Invest 16:56-60.
52. Pfeffer MA, Braunwald E, Moye LA, et al.: 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677.
53. Pittman JG, Cohen P: 1964. The pathogenesis of cardiac cachexia. N Engl J Med 271:403-409.
54. Powell JS, Clozel JP, Muller RK, et al.: 1989. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186-188.
55. Pratt RE, Dzau VJ: 1996. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 93:848-852.
56. Rao GN, Delafontaine P, Runge MS: 1995. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem 270:27,871-27,875.
57. Reiss K, Meggs LG, Li P, Olivetti G, Capasso JM, Anversa P: 1994. Upregulation of IGF1, IGF1-receptor, and late growth related genes in ventricular myocytes acutely after infarction in rats. J Cell Physiol 158:160-168.
58. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R: 1995. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55:3739-3741.
59. Ruzicka M, Yuan B, Harmsen E, Leenen FH: 1993. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation 87:921-930.
60. Ruzicka M, Skarda V, Leenen FH: 1995. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 92:3568-3573.
61. The SOLVD Investigators: 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302.
62. The SOLVD Investigators: 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691.
63. Stouffer GA, Owens GK: 1992. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ Res 70: 820-828.
64. Ververis JJ, Ku L, Delafontaine P: 1993. Regulation of insulin-like growth factor I receptors on vascular smooth muscle cells by growth factors and phorbol esters. Circ Res 72:1285-1292.
65. Wahlander H, Isgaard J, Jennische E, Friberg P: 1992. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 19:25-32.